

1 **Article**

2 **Title:**

3 Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors
4 of The Cancer Genome Atlas: exploration beyond single-agent therapy

5
6 **Authors:**

7 Christianne Persenaire, MD¹, Benjamin G. Bitler, PhD^{1,2}, and Bradley R. Corr, MD¹

8 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology,
9 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

10 2. Department of Obstetrics & Gynecology, Division of Reproductive Sciences,
11 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

12 3. Correspondence: christianne.persenaire@cuanschutz.edu

13

14 **Corresponding Author:**

15 Christianne Persenaire, MD

16 1665 Aurora Court

17 Anschutz Cancer Pavilion, 2nd Floor

18 Aurora, CO 80045

19 Phone: (484) 557-2111

20 Email: christianne.persenaire@cuanschutz.edu

21

22

23

24 **Word Counts:**

25 Abstract: 199

26 Manuscript: 2945

27

28 **Simple Summary:** Epithelial ovarian cancer can be highly lethal, with limited
29 therapeutic options for patients without BRCA mutations or non-homologous
30 recombination deficient disease. Folate receptor alpha (FR α)-targeting agents have
31 shown promise in the setting of platinum-sensitive and platinum-resistant ovarian
32 cancer, both alone and in combination with available therapies, but the relationship of
33 FR α to other treatment-driving biomarkers is unknown. This study identifies potential
34 targetable mutations in FR α -expressing tumors, including PIK3CA and FGF/R family
35 proteins, and provides a basis for future investigations of novel combinations of FR α -
36 targeting agents with PIK3CA, mTOR, FGF/R, and VEGF inhibitors.

37

38 **Abstract:**

39 Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for
40 patients with non-homologous recombination deficient (HRD) disease. Folate receptor
41 alpha (FOLR1/FR α)-targeting agents have shown promise both alone and in
42 combination with available therapies, but the relationship of FR α to other treatment-
43 driving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was queried to
44 assess protein and mRNA expression and mutational burden in patients with differential
45 FR α protein-expressing ovarian tumors, and the results referenced against the standard
46 324 mutations currently tested through FoundationOne Companion Diagnostics to

47 identify targets of interest. Of 585 samples within TCGA, 121 patients with serous
48 ovarian tumors for whom FR α protein expression was quantified were identified. FR α
49 protein expression significantly correlated with FOLR1 mRNA expression ($p=7.19 \times 10^{-14}$).
50 Progression free survival (PFS) for the FR α -high group (Q1) was 20.7 months,
51 compared to 16.6 months for the FR α -low group (Q4, Logrank, $p=0.886$). Overall
52 survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result
53 was not significant (Q1 vs. Q4, Logrank, $p=0.200$). Mutations more commonly
54 encountered in patients with high FR α -expressing tumors included PIK3CA and FGF
55 family proteins. Combinations of FR α -targeting agents with PI3K, mTOR, FGF(R) and
56 VEGF inhibitors warrant investigation to evaluate their therapeutic potential.

57

58 **Keywords:** epithelial ovarian cancer, folate receptor alpha, mirvetuximab soravtansine,
59 serous ovarian adenocarcinoma, targeted therapeutics

60

61

62

63

64

65

66

67

68

69

70 **1. Introduction:**

71 Ovarian cancer is the second most common gynecologic malignancy affecting women
72 in the United States and accounts for more deaths than all other gynecologic
73 malignancies combined. The standard of care for women with epithelial ovarian cancer
74 (EOC), including ovarian, fallopian tube, and primary peritoneal cancers, remains a
75 combination of cytoreductive surgery and taxane/platinum-based chemotherapies.
76 However, despite advancements in treatment with approved targeted therapies such as
77 poly(ADP-ribose) polymerase (PARP) inhibitors and vascular endothelial growth factor
78 (VEGF) inhibitors, disease recurrence still occurs at an alarming rate of 70-80% [1].
79 Recurrent disease most commonly progresses to a non-curable, platinum-resistant
80 state, and there remains a critical need to develop new therapeutic approaches.

81
82 Over the past decade, folate and its membrane-bound receptor have garnered
83 increased interest as a potential molecular target, as rapidly dividing cancer cells are
84 highly dependent on folate metabolism for DNA replication [2]. Folate receptor alpha
85 (FOLR1/FR α), specifically, is a transmembrane protein involved in cellular folate
86 transport whose expression is highly restricted in somatic tissues. Approximately 80% of
87 EOC constitutively overexpress this receptor, and elevated expression has been found
88 to be associated with a more aggressive tumor phenotype [3].

89
90 FR α -targeting agents range in design from monoclonal antibodies and small molecules
91 to folate-drug and antibody-drug conjugates (ADCs). Farletuzumab, for example, is a
92 fully humanized IgG1 antibody that targets FR α -positive cancer cells, while CT900 is a

93 small molecule thymidylate synthase inhibitor that is transported into tumor cells by its
94 high affinity for the FR α receptor [4]. Vintafolide is a folate-drug conjugate in which a
95 water-soluble folic acid derivative is linked through a peptide spacer to a potent
96 microtubule destabilizing agent called desacetylvinblastine monohydrazone, a vinca
97 alkaloid [4]. Once released within the cell, the vinca alkaloid acts to inhibit the beta-
98 tubulin polymerization necessary for cell division to induce cell cycle arrest.

99

100 ADCs are a novel class of antineoplastic agents that can utilize FR α as a biomarker-
101 driven target. These entities typically consist of a monoclonal antibody directed against
102 a tumor-associated antigen to which a cytotoxic agent ('payload') is conjugated; once
103 internalized, the payload is released to mediate its cytotoxic effects. This design has the
104 theoretical benefit of minimizing systemic toxicity while maximizing efficacy [5], and the
105 inherent capacity of FR α to internalize large molecules makes the receptor ideally
106 suited for targeting with ADCs such as mirvetuximab soravtansine (MIRV), STRO-002,
107 and MORab-202. Along with farletuzumab, these ADCs, as well as ELU001, a C'Dot
108 drug conjugate (NCT05001282); TPIV200/hu-FR-1, a multi-epitope anti-folate receptor
109 vaccine (NCT02764333) [6]; and ITL-306, a cell-based therapy derived from tumor-
110 infiltrating lymphocytes (TIL) whose activity increases when the agent encounters
111 tumor-specific FR α (NCT05397093); are under active investigation.

112

113 MIRV is an ADC with the most clinical evaluation in EOC of its drug class to date. It is
114 comprised of an FR α -binding antibody, cleavable linker, and the maytansinoid DM4, a
115 potent tubulin-targeting agent. Upon antigen binding, the FR α -ADC complex is rapidly

116 internalized and DM4 is released to induce cell cycle arrest and apoptosis. MIRV has
117 the additional benefit of bystander killing, as the cleavable linker design allows active
118 DM4 metabolites to diffuse from the antigen-positive tumor cells into neighboring cells
119 [7]. STRO-002 is another FR α -specific ADC comprised of an anti-FR α human IgG1
120 antibody, SP8166, conjugated to a cleavable DBCO-3-aminophenyl-hemiasterlin drug-
121 linker, while MORab-202 is an ADC in which farletuzumab and eribulin, a microtubule
122 inhibitor, are linked via cleavable cathepsin B [8].

123
124 Early clinical studies of MIRV in patients with platinum-resistant ovarian cancer (PROC)
125 showed promise, with an objective response rate (ORR) of 39% in a phase Ib trial with
126 few grade 3/4 toxicities [9]. In November of 2022, MIRV was granted accelerated
127 approval for FR α positive platinum-resistant ovarian cancer based on results from the
128 SORAYA trial (NCT04296890). Single-agent use in patients with up to three prior lines
129 of therapy, including required bevacizumab, demonstrated an ORR of 32.4%, including
130 five complete responses (CR), and a median duration of response (DOR) of seven
131 months. Response rates were similar regardless of the number of prior therapies
132 received, including PARP inhibitors [10]. More recently, encouraging results from the
133 international phase III randomized controlled trial, MIRASOL, comparing MIRV to
134 investigator's choice chemotherapy (IC) in patients with FR α positive PROC, were
135 presented at the 2023 Annual Meeting of the American Society of Clinical Oncology
136 (ASCO). Study authors found the median overall survival (OS) was 16.5 months with
137 MIRV vs. 12.8 months with IC (HR 0.67, p = 0.0046), while the median progression free
138 survival (PFS) was 5.62 months vs 3.98 months in each respective arm (HR 0.65, p

139 <0.0001). Objective response rate was 42.3% in the MIRV group versus 15.9% in the IC
140 group ($p < 0.0001$). These findings made MIRV the first treatment to demonstrate a PFS
141 and OS benefit in PROC compared to IC [11].

142
143 Other ADCs have had similarly encouraging results. In heavily pretreated patients with
144 advanced EOC, for example, STRO-002 had an ORR of 33% in 33 evaluable patients
145 across all FR α expression levels [12]. A phase I study of MORAb-202 in 22 patients
146 showed a CR, partial response (PR), and stable disease in one, nine, and eight
147 patients, respectively [13].

148
149 Prior efforts to target FR α with farletuzumab and vintafolide were hampered by limited
150 single-agent activity [14, 15]. However, vintafolide showed a statistically significant
151 improvement when used in combination with pegylated liposomal doxorubicin [16],
152 suggesting FR α -targeting agents may prove more effective when used in combination
153 with other agents [17]. Combinatory strategies with other FR α targeting agents are
154 currently under investigation. For example, clinical trials with MIRV in combination with
155 carboplatin (NCT04606914), rucaparib (NCT03552471), bevacizumab (NCT05445778),
156 pegylated liposomal doxorubicin or pembrolizumab (NCT02606305), and gemcitabine
157 (NCT02996825) are underway. Similarly, a study combining STRO-002 with
158 bevacizumab (NCT05200364) is actively recruiting.

159
160 As the relationship of FR α to other treatment-driving biomarkers is currently unknown,
161 the objective of this study was to analyze TCGA to assess protein/mRNA expression

162 and mutational burden in patients with differential FR α protein-expressing tumors and
163 identify potential targets for combination drug therapies.

164

165 **2. Materials & Methods:**


166 The Cancer Genome Atlas (TCGA) Ovarian Serous Cystadenocarcinoma PanCancer
167 Atlas was accessed via cBioportal (<http://www.cbioportal.org>) and queried in May 2022
168 to generate a list of patients for whom data regarding tumor levels of FR α protein
169 expression were available. Protein expression was calculated based on the Clinical
170 Proteomic Tumor Analysis Consortium (CPTAC, Figure 1A) [18].

171

172 We stratified patients into quartiles based on FR α expression, where Q1 = FR α high,
173 Q2 = FR α high-intermediate (int.), Q3 = FR α low-int., and Q4 = FR α low. These
174 quartiles were used to perform survival analyses and protein expression (Z-score)
175 analyses, as well as to examine mRNA expression and gene mutations as a function of
176 FR α expression. The results were then referenced against the standard 324 mutations
177 currently tested through FoundationOne Companion Diagnostics (CDx), including those
178 responsible for microsatellite instability, tumor mutational burden and loss of
179 heterozygosity, to identify targets of interest. Statistical analyses were conducted and
180 graphs generated in Prism GraphPad (v9.0) using Kaplan Meier curves, as well as
181 Logrank, Chi-squared, Spearman's rho, Pearson's rho, Benjamini-Hochberg and
182 student t-tests.

183

184



185

186 **Figure 1:** (A) Consort diagram establishing the TCGA PanCancer Atlas patient
 187 population for whom FR α expression data were available. (B) Columnar scatter plot of
 188 FR α protein expression values by quartile. (C) Columnar scatter plot of FR α mRNA
 189 expression by quartile. (D) Scatter plot depicting Pearson correlation of 0.75 between
 190 FOLR1 mRNA transcription and FR α protein expression. (E) Kaplan Meier curves
 191 depicting overall survival (OS) and progression free survival (PFS) by quartile.

192

193 **3. Results:**

194 Utilizing TCGA PanCancer Atlas (n=585), we identified 121 patients with serous ovarian
 195 tumors for whom FR α protein expression was quantified. Those patients were then

196 stratified into quartiles to assess for correlation with outcomes of interest (Figure 1A-B).
 197 TCGA PanCancer Atlas comparison of mRNA expression, protein expression (CPTAC)
 198 and genomic alterations was utilized across the four quartiles and data collected for
 199 18,695 mRNA transcripts and 7,620 proteins. Both mRNA expression and protein
 200 expression of FR α decreased in stepwise fashion from Q1 to Q4 (Figure 1B-C), and
 201 FOLR1 mRNA expression was significantly elevated (t-test; $p=7.19 \times 10^{-14}$; FDR
 202 $q=6.78 \times 10^{-10}$) across the different quartiles (Figure 1C). The Pearson correlation
 203 between FOLR1 mRNA transcription and FR α protein expression was 0.7452
 204 ($p < 0.0001$, Figure 1D).

205

206 When evaluating survival outcomes by quartile, PFS for the FR α -high group (Q1) was
 207 20.7 months, compared to 16.6 months for the FR α -low group (Q1 vs Q4, Logrank,
 208 $p=0.886$). Overall survival was 54.1 months versus 36.3 months, respectively; however,
 209 this result was not significant (Q1 vs. Q4, Logrank, $p=0.200$) (Figure 1E, Table 1).

210

211 **Table 1:** Overall survival and progression free survival in patients with EOC stratified by
 212 levels of tumor FR α expression; p-values derived by Log Rank test.

	Median Survival in Months				
	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	p-value
Overall Survival	54.1	31.3	39.4	36.3	0.3
Months (95% CI)	(43.2-NA)	(20.9-74.9)	(33.9-NA)	(24.2-70.1)	
Progression Free Survival	20.7	14.5	16	16.6	0.4
Months (95% CI)	(12.9-27.8)	(11.8-19.6)	(13.0-26.9)	(11.54-NA)	

213

214
215 To identify potential molecular targets correlating to FR α expression, data for the 324
216 genes assessed through FoundationOne CDx were collected, as these represent
217 mutations more frequently seen in patients with solid tumors, including EOC, and many
218 represent areas of active investigation for which targeted therapies exist, or are
219 currently in development. From these data, we compiled a list of the top thirty mutations
220 across the FR α quartiles, with results as noted in Table 2. Spearman's rank correlation
221 coefficient was calculated for protein expression for genes part of FoundationOne CDx
222 to identify proteins whose expression was strongly positively or negatively associated
223 with that of FR α protein; these results are shown in Table 3.

224
225 **Table 2:** Most common mutations encountered in tumors with high, high-intermediate,
226 low-intermediate, and low FR α expression; p-values derived by Chi squared test.

Gene Symbol	Number of mutations (%)				p-value
	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	
PIK3CA	9 (29.03%)	5 (16.67%)	7 (23.33%)	6 (20.69%)	0.703
ETV5	7 (22.58%)	6 (20.00%)	4 (13.33%)	4 (13.79%)	0.724
FGF12	7 (22.58%)	7 (23.33%)	6 (20.00%)	4 (13.79%)	0.793
KLHL6	7 (22.58%)	6 (20.00%)	4 (13.33%)	6 (20.69%)	0.814
RAD21	7 (22.58%)	9 (30.00%)	11 (36.67%)	7 (24.14%)	0.61
CCND1	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF19	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF3	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
FGF4	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507
MAP3K13	6 (19.35%)	7 (23.33%)	5 (16.67%)	4 (13.79%)	0.807
SOX2	6 (19.35%)	5 (16.67%)	5 (16.67%)	6 (20.69%)	0.971
IRF4	5 (16.13%)	3 (10.00%)	4 (13.33%)	1 (3.45%)	0.431
TIPARP	5 (16.13%)	3 (10.00%)	4 (13.33%)	3 (10.34%)	0.876
ERBB4	5 (16.13%)	2 (6.67%)	1 (3.33%)	0 (0.00%)	0.0698
ATR	5 (16.13%)	4 (13.33%)	2 (6.67%)	1 (3.45%)	0.332
TERT	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266
BCL6	4 (12.90%)	6 (20.00%)	4 (13.33%)	5 (17.24%)	0.856
RSPO2	4 (12.90%)	8 (26.67%)	3 (10.00%)	7 (24.14%)	0.257
XRCC2	4 (12.90%)	4 (13.33%)	4 (13.33%)	1 (3.45%)	0.539
BRD4	4 (12.90%)	2 (6.67%)	0 (0.00%)	6 (20.69%)	0.0532
NOTCH3	4 (12.90%)	2 (6.67%)	1 (3.33%)	6 (20.69%)	0.149
SDHA	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266
CCNE1	4 (12.90%)	4 (13.33%)	5 (16.67%)	7 (24.14%)	0.632
BRAF	4 (12.90%)	5 (16.67%)	3 (10.00%)	4 (13.79%)	0.899
ERBB3	4 (12.90%)	1 (3.33%)	0 (0.00%)	1 (3.45%)	0.113
MCL1	4 (12.90%)	2 (6.67%)	1 (3.33%)	2 (6.90%)	0.552
BRCA1	3 (9.68%)	1 (3.33%)	1 (3.33%)	2 (6.90%)	0.665
BTG2	3 (9.68%)	2 (6.67%)	0 (0.00%)	1 (3.45%)	0.344
CDKN1A	3 (9.68%)	3 (10.00%)	1 (3.33%)	0 (0.00%)	0.27
FOXL2	3 (9.68%)	4 (13.33%)	1 (3.33%)	1 (3.45%)	0.373

227

228

229 **Table 3:** Proteins with an absolute Spearman’s Rho >0.98 suggesting association with
 230 FOLR1 expression; p-values derived by student’s t-test.

Gene Symbol	Gene Name	FOLR1 Protein Expression (Z-score)				Rho value	p-value
		Q1 (High)	Q2 (High Int)	Q3 (Low Int)	Q4 (Low)		
CTNNA1	alpha catenin	0.14	0.03	-0.02	-0.07	0.991	0.002
FH	fumarate hydratase	0.16	0	-0.05	-0.12	0.985	0.013
CDH1	e-cadherin	0.09	0.01	-0.08	-0.21	0.984	0.008
SDHA	succinate dehydrogenase complex flavoprotein subunit A	0.09	0	-0.01	-0.07	0.981	0.110
SRC	proto-oncogene C-Src	-0.08	-0.05	0.01	0.05	-0.977	0.271
AKT3	protein kinase B, gamma	-0.2	-0.01	0.04	0.12	-0.981	0.529
NF1	neurofibromin 1	-0.09	-0.06	-0.01	0.03	-0.982	0.627
QKI	quaking homolog, KH domain RNA binding	-0.05	0.03	0.07	0.13	-0.999	0.012

231
 232
 233 Only 160/324 genes on the FoundationOne CDx were identified via CPTAC. Quaking
 234 Homolog, KH Domain RNA Binding (QKI) was the most negatively correlated (Pearson r
 235 = -0.996) and Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) was
 236 the most positively correlated (Pearson r = 0.993). BRCA1 protein expression was
 237 undetectable and BRCA2 protein expression did not correlate with FR α protein
 238 expression (Pearson r = 0.27). Data regarding protein expression for other genes in the
 239 HRD pathway were available only for ATM, CHEK2 and NBS1, and also showed no
 240 correlation.

241
 242 **4. Discussion:**

243 Targeting FR α is an area of active investigation and one that holds significant promise.
 244 In this study, we used TCGA to identify potential molecular targets that could potentiate

245 the ORR of FR α -targeting agents and improve their therapeutic efficacy for patients with
246 EOC, particularly those with non-HRD, platinum-resistant disease. We identified an
247 increased frequency of potentially targetable PIK3CA and FGF family protein mutations
248 in FR α -expressing tumors.

249

250 ***Results in the Context of Published Literature:***

251 Although early studies of single-agent MIRV, STRO-002, and MORAb-202 suggested
252 these have anti-tumor activity, several combinatorial approaches are under active
253 investigation. MIRV, for example, is being studied in combination with various
254 chemotherapies and targeted therapies such as pembrolizumab and bevacizumab
255 (NCT02606305). In 2018, as part of FORWARD II, Moore et al. published data from the
256 phase 1b escalation study of MIRV in combination with carboplatin in patients with
257 platinum-sensitive ovarian cancer (PSOC), which found a 71% ORR, including three CR
258 and nine PR, and a median PFS of 15 months [19]. Among others, these findings
259 prompted a single arm, phase II trial of carboplatin and MIRV for first-line treatment of
260 patients with advanced, FR α -positive EOC receiving neoadjuvant chemotherapy
261 (NCT04606914). A randomized phase II trial of MIRV in FR α -high, recurrent PSOC
262 also began enrolling patients in September 2021, with the goal of comparing platinum-
263 based chemotherapy followed by PARPi (if indicated) to carboplatin + MIRV followed by
264 MIRV monotherapy (NCT04274426).

265

266 For patients with PROC, another expansion cohort from FORWARD II found a
267 confirmed ORR of 43% in patients treated with a combination of MIRV and

268 pembrolizumab, with a median DOR of 6.9 months and median PFS of 5.2 months [20].
269 The same phase Ib study included a cohort of patients with PROC who received MIRV
270 in combination with bevacizumab; for these patients, the confirmed ORR was 39%,
271 including five CR and 21 PR; median PFS was 6.9 months. Patients who were
272 bevacizumab-naïve, less heavily pretreated, and whose tumors had medium/high FR α
273 expression had an ORR of 56% with a median DOR of 12 months and PFS of 9.9
274 months [21]. Given these findings, FORWARD II looked at the combination of MIRV,
275 carboplatin and bevacizumab followed by MIRV and bevacizumab maintenance therapy
276 in 41 patients with recurrent PSOC, with a confirmed ORR of 83%, median DOR of 10.9
277 months and PFS of 12.8 months [22]. These data suggest synergistic and durable anti-
278 tumor effects of combinatorial approaches, and more trials are in active development.
279
280 In our effort to identify potential targets, we found *PIK3CA* is mutated in 29% of tumors
281 with high FR α expression. *PIK3CA*, or phosphatidylinositol-4,-5-bisphosphate 3-
282 kinase catalytic subunit alpha, is an oncogene that has been implicated in several
283 cancers, including breast, colon, liver, and stomach cancers [23]. Point mutations in this
284 gene can cause hyperactivation of the alpha isoform (p110a) of PI3K, which in turn
285 results in constitutive activation of the intracellular PI3K/Akt signaling pathway. This
286 pathway is linked to several critical physiologic and pathophysiologic functions,
287 including those that drive tumor progression, such as cell proliferation, growth,
288 metabolism, angiogenesis, and motility [24]. Several PI3K inhibitors, such as alpelisib, a
289 small molecule, α -specific PI3K inhibitor that selectively inhibits p110a, are being
290 evaluated, and early work suggests that *PIK3CA*-mutated cancers are sensitive to

291 treatment with these agents [25]. When given in combination with standard of care
292 therapies, as with olaparib in ovarian cancer or fulvestrant in breast, these drugs may
293 work synergistically to overcome tumor resistance and sensitize the tumor cells to
294 treatment with currently approved agents [26, 27].

295
296 The propensity toward *PIK3CA* mutations in $FR\alpha$ high tumors also provides a basis for
297 investigating combinations of $FR\alpha$ -targeting agents with mammalian target of
298 rapamycin, or mTOR, inhibitors. This is because activation of the PI3K/Akt signaling
299 pathway results in downstream activation of the mTOR pathway. As with the PI3K/Akt
300 pathway, mTOR plays a key role in regulating cell proliferation, and functions as a
301 regulator of autophagy and apoptosis; thus, alterations in this pathway can lead to
302 unchecked cell proliferation. In ovarian cancer, specifically, the PI3K/Akt/mTOR
303 pathway has been found to activated in approximately 70% of cases and has been
304 linked to higher invasive and migratory capacity. The mTOR inhibitors temsirolimus and
305 everolimus have been studied in clinical trials of patients with recurrent EOC and had
306 promising results [28].

307
308 Importantly, while VEGF was not one of the top mutations identified based on $FR\alpha$
309 expression, receptor binding of VEGFR2 has been found to activate PI3K and Akt.
310 Although the mechanism by which this occurs is not fully understood, it is thought to
311 occur by TSA α -mediated activation of Src family kinases, which engage the receptor
312 tyrosine kinase Axl to trigger ligand-independent autophosphorylation and promote
313 association with PI3K and activation of Akt [29]. This association between VEGFR2 and

314 PI3K/Akt activation, as well as the higher rate of PIK3CA mutations in FR α -high tumors,
315 may provide a mechanistic basis for the promising therapeutic efficacy seen in the early
316 trials of patients treated with combinations of MIRV with bevacizumab mentioned
317 previously. A phase 3 trial to evaluate MIRV in combination with bevacizumab versus
318 bevacizumab alone in PSOC (GLORIOSA) began recruiting patients in December 2022
319 (NCT 05445778).

320
321 Other mutations more frequently observed in FR α -high tumors were those of the
322 fibroblast growth factor, or FGF, family, including FGF3 (19.35% vs. 0%), FGF4
323 (19.35% vs. 0%), FGF12 (22.58% vs. 13.79%), and FGF19 (19.35% vs. 0%). Broadly
324 speaking, the fibroblast growth factor receptor (FGFR) family of receptor tyrosine
325 kinases consists of four transmembrane receptors, FGFR1-4, and twenty-two known
326 FGF ligands that interact to activate downstream signaling pathways through an
327 intracellular domain. One such pathway is the extracellular signal-regulated kinase
328 (ERK)/mitogen-activated protein kinase (MAPK) pathway, which promotes cell survival,
329 proliferation, angiogenesis, and differentiation—processes exploited in malignant
330 transformation and tumorigenesis [30]. Several agents targeting FGF have been
331 developed for clinical use, ranging from selective tyrosine kinase inhibitors and
332 monoclonal antibodies to ADCs and FGF ligand traps. Two anti-FGFR therapies have
333 been approved by the Food and Drug Administration to date, including erdafitinib for
334 FGFR-3-altered urothelial cancer, and pemigatinib for FGFR-2 fusion
335 cholangiocarcinoma [30]. Lenvatinib, an oral receptor tyrosine kinase inhibitor that has
336 activity against FGFR1-4, as well as VEGFR1-3, platelet derived growth factor receptor-

337 beta, and the RET and kit proto-oncogenes, is currently approved for patients with
338 advanced endometrial cancer without microsatellite instability. Given the higher FGF
339 mutation rate seen in FR α -high tumors in this study, investigation into combinations of
340 FR α -targeting therapies with anti-FGF/R modalities may prove a fruitful area of inquiry.

341
342 It should be noted that the BRCA and HRD pathway genes did not demonstrate a clear
343 correlation with FR α expression. The combinatory strategy with PARP inhibitors was
344 first assessed in NCT03552471 utilizing MIRV and rucaparib in recurrent ovarian,
345 fallopian tube, peritoneal or endometrial cancers. The ORR was 29% in the ovarian
346 cancer cohort with a PFS >6months in 47.1% [31]. The lack of correlation of FR α
347 expression and BRCA/HRD demonstrates that a synergistic effect between the two is
348 unlikely, but an additive effect in distinct patient populations may warrant future
349 investigation.

350

351 ***Strengths and Limitations:***

352 A pitfall from previous trials was the method of determining FR α expression in primary
353 tumors, which is critical, as subsequent trials observed a strong positive correlation
354 between FR α expression and ORR. One of the strengths of this analysis was the finding
355 that FR α protein expression significantly correlates with FOLR1 mRNA expression. This
356 raises the possibility of examining mRNA expression in lieu of immunohistochemical
357 based assays in future studies. Limitations of this study include those intrinsic to the use
358 of publicly available datasets such as TCGA PanCancer Atlas, which has restricted
359 scope with a limited number of analyzed samples. In this case, data regarding FR α

360 expression were available for only 121 of 585 patients included in the PanCancer Atlas.
361 An additional limitation is the confounding effect of chromosomal locus on the
362 amplification or overexpression of a target of interest. FOLR1 is found on chromosome
363 11; the differential expression of proteins found on chromosome 11 may thus be related
364 to proximity to the $FR\alpha$ gene, resulting in similar transcriptional regulation.

365

366 **5. Conclusion:**

367 To date, only a few targetable mutations have been examined as part of combinatorial
368 approaches to the treatment of ovarian cancer; based on our findings, there are multiple
369 avenues for further investigation that have the potential to improve outcomes for
370 patients with advanced EOC who currently lack other therapeutic options. In light of the
371 promising results of MIRASOL, this work provides a compelling indication to explore
372 and/or expand upon potential drug combinations of $FR\alpha$ -targeting agents with PI3K,
373 mTOR and FGF/FGFR inhibitors, and bevacizumab to evaluate their therapeutic
374 potential in advanced EOC.

375

376 **Funding:**

377 This work was supported in part by the University of Colorado Cancer Center's Shared
378 Resource, funded by NCI grant P30CA046934. This funding did not play a role in study
379 design; collection, analysis, or interpretation of data; writing of the report; or the decision
380 to submit the article for publication.

381

382 **Author Contributions:**

383 Each author was actively involved in this research and approved the final version for
384 submission. The individual contributions are listed below:
385 Christianne Persenaire: drafted written manuscript, created figures, and contributed to
386 reviews
387 Benjamin G. Bitler: conceptual design, drafted written manuscript, created figures, and
388 contributed to reviews
389 Bradley R. Corr: conceptual design, drafted written manuscript, and contributed to
390 reviews

391

392 **Conflicts of Interest:**

393 Dr. Bitler is funded via unrelated grants from DOD, NIH, ACS, and OCRA. Dr. Corr has
394 received honorarium for advisory boards on Merck, AstraZeneca, Novocure, GSK,
395 Immunogen, and Imvax. Dr. Corr also receives research funding from Clovis Oncology.
396 Dr. Persenaire declares no conflicts of interest.

397

398

399

400

401

402

403

404

405

406 **References:**

- 407 1. Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian
408 cancer. *Ann Oncol*. 2017;28(suppl_8):viii51-viii56. Doi:10.1093/annonc/mdx441
- 409 2. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate
410 receptor alpha antagonists mechanism of action in ovarian cancer. *Gynecol Oncol*.
411 2013;131(2):493-498.'
- 412 3. Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer
413 treatment. *Oncotarget*. 2016;7(32):52553-52574.
- 414 4. Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in
415 oncology. *Nat Rev Clin Oncol*. 2020;17(6):349-359. doi:10.1038/s41571-020-0339-5
- 416 5. Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. *Gynecol*
417 *Oncol*. 2019;153(3):694-702.
- 418 6. Zamarin D, et al; Abstract AP27: A phase 2 study of TPIV200/HUFR-1 (a multi-
419 epitope folate receptor alpha vaccine) in combination with durvalumab in patients
420 with platinum resistant ovarian cancer. *Clin Cancer Res* 15 November 2019; 25
421 (22_Supplement): AP27. <https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27>
- 422 7. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab
423 soravtansine versus chemotherapy in patients with platinum-resistant ovarian
424 cancer: primary analysis of FORWARD I. *Ann Oncol*. 2021;32(6):757-765.
- 425 8. Manzano A, Ocaña A. Antibody-Drug Conjugates: A Promising Novel Therapy for
426 the Treatment of Ovarian Cancer. *Cancers (Basel)*. 2020;12(8):2223. Published
427 2020 Aug 9. Doi:10.3390/cancers12082223

- 428 9. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab
429 soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate
430 (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian
431 cancer. *Gynecol Oncol*. 2020;157(2):379-385.
- 432 10. ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of
433 Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting.
434 BusinessWire. 19 Mar 2022. Accessed 25 Aug 2022. Online, Available
435 <[https://investor.immunogen.com/news-releases/news-release-details/immunogen-](https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-full-results-positive-pivotal-soraya-trial)
436 [presents-full-results-positive-pivotal-soraya-trial](https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-full-results-positive-pivotal-soraya-trial)> n.pag
- 437 11. Moore KN, Angelergues A, Konecny GE, Banerjee SN, Pignata S, Colombo N, et al.
438 Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab
439 soravtansine vs. investigator's choice of chemotherapy in platinum-resistant,
440 advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers
441 with high folate receptor-alpha expression. *JCO*. 2023 Jun
442 10;41(17_suppl):LBA5507–LBA5507.
- 443 12. Naumann RW, Marin LP, Oaknin, A, et al. STRO-002-GM2: A Phase 1 Open-Label,
444 Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-
445 Folate Receptor Alpha Antibody Drug Conjugate in Combination with Bevacizumab
446 in Patients with Advanced Epithelial Ovarian Cancer. Abstract presented at ASCO
447 2022 Annual Meeting, Chicago, IL.
- 448 13. Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-Human Phase 1 Study of MORAb-
449 202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin

- 450 Mesylate, in Patients with Folate Receptor- α -Positive Advanced Solid Tumors. *Clin*
451 *Cancer Res.* 2021;27(14):3905-3915. Doi:10.1158/1078-0432.CCR-20-4740
- 452 14. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized
453 monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a
454 phase I study. *Clin Cancer Res.* 2010;16(21):5288-5295. doi:10.1158/1078-
455 0432.CCR-10-0700
- 456 15. Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145
457 (Vintafolide) in patients with refractory solid tumors. *J Clin Oncol.* 2012;30(32):4011-
458 4016. doi:10.1200/JCO.2011.41.4946
- 459 16. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II
460 trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in
461 combination versus PLD alone in patients with platinum-resistant ovarian cancer. *J*
462 *Clin Oncol* 2013;31:4400-4406.
- 463 17. Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab Soravtansine (IMGN853), a Folate
464 Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of
465 Standard of Care Therapeutics in Ovarian Cancer Models. *Neoplasia.*
466 2016;18(12):775-784. Doi:10.1016/j.neo.2016.11.002
- 467 18. Data used in this publication were generated by the Clinical Proteomic Tumor
468 Analysis Consortium (NCI/NIH)
- 469 19. Moore KN, O'Malley DM, Vergote I, et al. Safety and activity findings from a phase
470 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-
471 targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients

- 472 with platinum-sensitive ovarian cancer. *Gynecol Oncol*. 2018;151(1):46-52.
473 Doi:10.1016/j.ygyno.2018.07.017
- 474 20. Matulonis U, Moore KN, Martin, LP, Vergote IB, Castro C, Gilbert L, Malek K, Birrer
475 MJ, O'Malley DM. Mirvetuximab soravtansine, a folate receptor alpha (FR α)-
476 targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant
477 ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a
478 phase Ib study. *Abstracts Gynaecological Cancer 10/2018*: Vol 29 Supplement 8,
479 VIII339. doi:10.1093/annonc/mdy285.157.
- 480 21. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab
481 soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate
482 (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian
483 cancer. *Gynecol Oncol*. 2020;157(2):379-385. Doi:10.1016/j.ygyno.2020.01.037
- 484 22. O'Malley DM, Richardson DL, Vergote IB, Gilbert L, Castro C, Provencher D,
485 Matulonis UA, Mantia-Smaldone G, Martin L, Zweidler-McKay PA, Moore KN.
486 Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FR α)-targeting antibody-
487 drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab
488 (BEV): Final results from a study in patients with recurrent platinum sensitive ovarian
489 cancer. *Annals of Oncology* (202) 31 (supp_4):S551-S589. DOI:
490 10.1016/annonc/annonc276.
- 491 23. Safran M, Rosen N, Twik M, BarShir R, Iny Stein T, Dahary D, Fishilevich S, and
492 Lancet D. *The GeneCards Suite Chapter, Practical Guide to Life Science*
493 *Databases (2022) pp 27-56*

- 494 24. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human
495 cancers. *Br J Cancer*. 2006;94(4):455-459. doi:10.1038/sj.bjc.6602970
- 496 25. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer:
497 Clinical Implications and Adverse Effects. *Int J Mol Sci*. 2021;22(7):3464. Published
498 2021 Mar 27. doi:10.3390/ijms22073464
- 499 26. Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α -specific PI3K
500 inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and
501 dose-expansion phase 1b trial. *Lancet Oncol*. 2019;20(4):570-580.
502 doi:10.1016/S1470-2045(18)30905-7
- 503 27. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for *PIK3CA*-Mutated, Hormone
504 Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2019;380(20):1929-
505 1940. doi:10.1056/NEJMoa1813904
- 506 28. Gasparri ML, Bardhi E, Ruscito I, et al. PI3K/AKT/mTOR Pathway in Ovarian Cancer
507 Treatment: Are We on the Right Track? *Geburtshilfe Frauenheilkd*.
508 2017;77(10):1095-1103. doi:10.1055/s-0043-118907
- 509 29. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of
510 PI3K/Akt. *EMBO J*. 2012;31(7):1692-1703. doi:10.1038/emboj.2012.21
- 511 30. Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer:
512 genetic alterations, diagnostics, therapeutic targets and mechanisms of
513 resistance. *Br J Cancer*. 2021;124(5):880-892. doi:10.1038/s41416-020-01157-0
- 514 31. Backes F, Fowler J, Copeland L, Wei L, O'Malley D, Cohn D, Cosgrove C, Hays J,
515 Bixel K. Phase I Study of Mirvetuximab Soravtansine (Mirv) and Rucaparib for
516 Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

- 517 International Journal of Gynecological Cancer. 2021;31:A13-A4. doi: 10.1136/ijgc-
- 518 2021-IGCS.24. PubMed PMID: WOS:000773625600025.